Xlibris releases Collateral Damage:
Xlibris, the self-publishing services provider, announced today the release of Collateral Damage:
After European tests found the key ingredient increased the risk of serious heart problems, Abbott Laboratories on Oct. 8 said it was pulling its obesity drug Meridia from the US market.